CN1126536C - 用于控制释放活性物质的药物组合物 - Google Patents

用于控制释放活性物质的药物组合物 Download PDF

Info

Publication number
CN1126536C
CN1126536C CN98803222A CN98803222A CN1126536C CN 1126536 C CN1126536 C CN 1126536C CN 98803222 A CN98803222 A CN 98803222A CN 98803222 A CN98803222 A CN 98803222A CN 1126536 C CN1126536 C CN 1126536C
Authority
CN
China
Prior art keywords
layer
active substance
pharmaceutical composition
composition according
homogeneous mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN98803222A
Other languages
English (en)
Chinese (zh)
Other versions
CN1250371A (zh
Inventor
D·法那拉
M·比瓦尔
A·伯盖勒
M·德勒斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Publication of CN1250371A publication Critical patent/CN1250371A/zh
Application granted granted Critical
Publication of CN1126536C publication Critical patent/CN1126536C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN98803222A 1997-03-14 1998-03-13 用于控制释放活性物质的药物组合物 Expired - Fee Related CN1126536C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE9700225 1997-03-14
BE9700225A BE1011045A3 (fr) 1997-03-14 1997-03-14 Compositions pharmaceutiques pour la liberation controlee de substances actives.

Publications (2)

Publication Number Publication Date
CN1250371A CN1250371A (zh) 2000-04-12
CN1126536C true CN1126536C (zh) 2003-11-05

Family

ID=3890403

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98803222A Expired - Fee Related CN1126536C (zh) 1997-03-14 1998-03-13 用于控制释放活性物质的药物组合物

Country Status (19)

Country Link
US (3) US6699502B1 (OSRAM)
EP (1) EP1007005B1 (OSRAM)
JP (1) JP2001524950A (OSRAM)
KR (1) KR100500775B1 (OSRAM)
CN (1) CN1126536C (OSRAM)
AT (1) ATE275943T1 (OSRAM)
AU (1) AU736052B2 (OSRAM)
BE (1) BE1011045A3 (OSRAM)
BR (1) BR9808239A (OSRAM)
CA (1) CA2283133C (OSRAM)
DE (1) DE69826290T2 (OSRAM)
ES (1) ES2229483T3 (OSRAM)
ID (1) ID22980A (OSRAM)
IL (1) IL131292A (OSRAM)
NZ (1) NZ337345A (OSRAM)
PL (1) PL190735B1 (OSRAM)
RO (1) RO120602B1 (OSRAM)
RU (1) RU2179017C2 (OSRAM)
WO (1) WO1998041194A1 (OSRAM)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1050306A (ja) * 1996-07-31 1998-02-20 Toyota Autom Loom Works Ltd 水素吸蔵合金電極の製造方法
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
JP2001107258A (ja) * 1999-10-06 2001-04-17 Hitachi Ltd 無電解銅めっき方法とめっき装置および多層配線基板
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP1118321A1 (fr) * 2000-01-14 2001-07-25 Ucb, S.A. Compositions pharmaceutiques solides pour la libération contrôlée de substances actives
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
EP2283829A1 (en) * 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
SI1404304T1 (sl) * 2001-06-28 2009-10-31 Ucb Farchim Sa Z I Planchy Tableta, obsegajoča cetirizin in psevdoefedrin
IL159287A0 (en) * 2001-06-28 2004-06-01 Ucb Farchim Sa Tablet comprising cetirizine and pseudoephedrine
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
AU2003202550A1 (en) * 2002-01-09 2003-07-24 Ucb, S.A. Pharmaceutical formulations with modified release
CA2481025A1 (en) * 2002-04-04 2003-10-16 Tanya Havlir Palatable chewable tablet
EP1545468A4 (en) * 2002-09-20 2007-06-20 Alpharma Inc SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
CA2507042A1 (en) * 2002-12-06 2004-06-24 Ucb Farchim, S.A. Tablet comprising efletirizine and pseudoephedrine
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050281875A1 (en) * 2003-12-17 2005-12-22 Sovereign Pharmaceuticals, Ltd. Promethazine containing dosage form
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050232986A1 (en) * 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US20050232987A1 (en) * 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug
US20060029664A1 (en) * 2004-08-04 2006-02-09 Sovereign Pharmaceuticals, Ltd. Dosage form containing carbetapentane and another drug
US7897172B2 (en) * 2004-05-18 2011-03-01 L. Perrigo Company Tablets exhibiting reduced drug release variability
US9308164B2 (en) 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
WO2006022996A2 (en) * 2004-08-04 2006-03-02 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US7529255B2 (en) * 2005-04-21 2009-05-05 Microsoft Corporation Peer-to-peer multicasting using multiple transport protocols
HRP20141185T1 (hr) * 2005-07-26 2015-01-30 Ucb Pharma Sa Farmaceutski pripravci koji sadrže levetiracetam i proces za njihovu pripremu
EA014739B1 (ru) * 2005-09-09 2011-02-28 Лабофарм Инк. Композиция тразодона для введения один раз в день
RU2008113439A (ru) 2005-09-09 2009-10-20 Лабофарм Инк. (CA) Композиции с замедленным высвобождением лекарственного средства
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
SG169334A1 (en) * 2006-01-21 2011-03-30 Abbott Gmbh & Co Kg Dosage form and method for the delivery of drugs of abuse
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
KR100753480B1 (ko) * 2006-01-27 2007-08-31 씨제이 주식회사 잘토프로펜 함유 서방성 정제 및 그 제조방법
US20070253927A1 (en) * 2006-04-13 2007-11-01 Gwenaelle Jegou Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
US20100172984A1 (en) * 2006-06-06 2010-07-08 Bijay Kumar Padhi tablet dosage form comprising cetirizine and pseudoephedrine
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
MX2008016349A (es) * 2006-06-19 2009-01-28 Accu Break Technologies Inc Formas segmentadas de dosificacion farmaceutica.
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP2068713B1 (en) 2006-09-25 2012-07-18 Koninklijke Philips Electronics N.V. Shifting an object for complete trajectories in rotational x-ray imaging
JP2010522135A (ja) 2006-10-09 2010-07-01 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
WO2008064192A2 (en) 2006-11-21 2008-05-29 Mcneil-Ppc, Inc. Modified release analgesic suspensions
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
JP5453280B2 (ja) * 2007-10-16 2014-03-26 ラボファーム インコーポレイテッド アセトアミノフェンおよびトラマドールを持続的に放出するための二層組成物
WO2009067605A2 (en) * 2007-11-21 2009-05-28 The Procter & Gamble Company Preparations, methods and kits useful for treatment of cough
WO2009076764A1 (en) * 2007-12-17 2009-06-25 Labopharm Inc. Misuse preventative, controlled release formulation
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
CN102316857A (zh) 2008-12-16 2012-01-11 莱博法姆公司 防止误用的控释配方
EP2381937A2 (en) 2008-12-31 2011-11-02 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
EP2477610A1 (en) 2009-09-17 2012-07-25 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
CA2798702A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms
CN102302497A (zh) * 2011-05-18 2012-01-04 天圣制药集团股份有限公司 一种治疗过敏性鼻炎的制剂及其制备方法
ES2795291T3 (es) 2013-02-13 2020-11-23 Procter & Gamble Medicamento con sabor a anís
KR102070076B1 (ko) * 2013-05-03 2020-01-29 주식회사 제닉 탄산 함유 입자를 포함하는 필름
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
BR112016020877B1 (pt) 2014-03-11 2022-11-29 Redhill Biopharma Ltd Uso de ondansetron, uso de um núcleo compreendendo uma matriz polímera não iônica e comprimido
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
RU2687715C1 (ru) * 2018-05-07 2019-05-15 Федеральное государственное бюджетное учреждение науки Институт горного дела Дальневосточного отделения Российской академии наук Способ комбинированной разработки россыпных месторождений золота
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
EP3965733A4 (en) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE
KR102073185B1 (ko) * 2019-07-16 2020-02-04 (주)위바이오트리 활성성분을 포함하는 변성 다중층 수산화물 구조체를 포함하는 금속 수산화물 복합체 및 이의 제조 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US477033A (en) * 1892-06-14 Bicycle
US4684516A (en) 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
EP0205336B1 (en) 1985-06-11 1991-09-11 Teijin Limited Oral sustained release pharmaceutical preparation
DE3524572A1 (de) 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
JPS6396126A (ja) 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd 安定化組成物
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
GB8724763D0 (en) 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
IE60383B1 (en) * 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US5411748A (en) 1992-10-22 1995-05-02 Song Moon K Prostate extract supplemented with zinc
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
WO1995034291A1 (en) * 1994-06-15 1995-12-21 Dumex-Alpharma A/S Pellets
RU2065299C1 (ru) * 1994-07-15 1996-08-20 Акционерное общество закрытого типа "Олвик" Ноотропное и транквилизирующее средство
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
CA2277220A1 (en) * 1997-01-10 1998-07-16 Abbott Laboratories Tablet for the controlled release of active agents
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.

Also Published As

Publication number Publication date
DE69826290T2 (de) 2005-02-17
US7083807B2 (en) 2006-08-01
WO1998041194A1 (fr) 1998-09-24
CA2283133C (fr) 2006-07-25
BE1011045A3 (fr) 1999-04-06
US20020110596A1 (en) 2002-08-15
KR100500775B1 (ko) 2005-07-12
BR9808239A (pt) 2000-05-16
PL190735B1 (pl) 2005-12-30
JP2001524950A (ja) 2001-12-04
AU6387398A (en) 1998-10-12
KR20000076269A (ko) 2000-12-26
RU2179017C2 (ru) 2002-02-10
RO120602B1 (ro) 2006-05-30
IL131292A (en) 2004-07-25
CA2283133A1 (fr) 1998-09-24
PL335832A1 (en) 2000-05-22
IL131292A0 (en) 2001-01-28
ID22980A (id) 1999-12-23
ATE275943T1 (de) 2004-10-15
EP1007005A1 (fr) 2000-06-14
EP1007005B1 (fr) 2004-09-15
CN1250371A (zh) 2000-04-12
ES2229483T3 (es) 2005-04-16
AU736052B2 (en) 2001-07-26
NZ337345A (en) 2000-04-28
HK1026152A1 (en) 2000-12-08
US6699502B1 (en) 2004-03-02
DE69826290D1 (de) 2004-10-21
US20040086563A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
CN1250371A (zh) 用于控制释放活性物质的药物组合物
CN1198598C (zh) 亲水性/亲脂性聚合物骨架剂型
CN1111404C (zh) 控释的羟丁宁制剂
CN1227004C (zh) 治疗充血性心力衰竭的部分脂肪酸氧化抑制剂
CN1202815C (zh) 含有曲马朵糖精盐的持续释放给药剂型
CN1146410C (zh) 控制释放制剂
CN1809341A (zh) 多层口溶型片剂
CN1284867A (zh) 生产咀嚼分散片的方法
CN1681509A (zh) 含拉莫三嗪的缓释制剂
HK1044284B (zh) 雷诺嗪持续释放制剂
CN1302605A (zh) 缓释的口服给药组合物
CN1527706A (zh) 含特比萘芬的药物组合物及其应用
CN1499960A (zh) 时间治疗剂型
CN1520285A (zh) 包含西替利嗪和伪麻黄碱的片剂
CN1446535A (zh) 盐酸[R－(Z)]－α－甲氧亚氨基－α－(1－氮杂双环[2.2.2]辛－3－基)乙腈控释剂型
CN1589906A (zh) 5ht4激动剂或拮抗剂的新型口服制剂
CN1527700A (zh) 制备苯妥英钠剂型的压缩方法
CN1662237A (zh) 控释医药组合物
CN1649569A (zh) 控释剂型
CN1115150C (zh) 用于治疗偏头痛的含有布洛芬和多潘立酮的药用组合物
CN1929823A (zh) 托塞米缓释剂型
CN1684681A (zh) 比西发定制剂
CN1321084A (zh) 含有布洛芬和多潘立酮的药用组合物
CN1286844C (zh) 含有血管紧张素ⅱ受体拮抗剂和b族维生素的药物组合物
US20080206331A1 (en) Tablet comprising efletirizine and pseudoephedrine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee